Home | Cha Therapeutics

Harnessing the Power of Collaborative Agents For Epigenetics Plus Reprograming of Cancer Immunotherapies

Cha Therapeutics Inc. is an early-stage, privately held, Massachusetts-based biotechnology start-up developing a proprietary epigenetic therapy that improves cancer patient outcomes.

Our mission is to develop groundbreaking drug combinations to treat cancers that have evaded the immune system, particularly those driven by Wnt signaling.

Our unique approach leverages a combination of compounds designed to re-program tumor cells, making them more susceptible to immune checkpoint inhibitors and other immunotherapies.

Learn More

Company-Owned Proprietary Intellectual Property

Our intellectual property forms the cornerstone of our innovative approach, offering a unique advantage in the development of cancer therapies.

Sensitizing Tumors to Immune Therapies

We are pioneering strategies to enhance tumor responsiveness to immune checkpoint inhibitors, making resistant cancers treatable.

Deep Pre-Clinical Discovery Platform

Our robust pre-clinical discovery platform drives the identification and development of transformative drug combinations.

Re-Programming the Tumor and Immune Environment

By re-engineering the tumor microenvironment, we aim to convert "cold" tumors into "hot" tumors, unlocking their potential for immunotherapy.

The Urgent Need: Overcoming the Limitations of Current Cancer Treatments

Immune checkpoint inhibitors have revolutionized cancer treatment, offering new hope to patients with specific tumor types by harnessing the immune system to target and destroy tumors. However, their effectiveness is limited to "hot" tumors, those that are already engaged by the immune system.

Unfortunately, most cancers are "cold," meaning they fail to activate the immune response and respond poorly to these life-saving treatments. This presents one of the most significant challenges in modern oncology.

At Cha Therapeutics, we are addressing this issue directly. Our research is focused on developing innovative strategies to transform "cold" tumors into "hot" tumors, thereby enhancing their response to immune checkpoint inhibitors. By overcoming the limitations of current therapies, we aim to expand the range of cancers that can benefit from immune-based treatments, ultimately making them more effective for a broader patient population.

We are actively seeking partnerships to accelerate our mission and bring these groundbreaking therapies to patients in need. Together, we can reshape the future of cancer care.

Key Milestones

Cha Therapeutics, Inc. was Incorporated on February 21, 2019.

Corporate and Intellectual Property Partner:

Provisional Patent Filed: November 14, 2018.

Full Patent Filed: November 13, 2019.

Extensive Proof of Concept (>10M grants to CEO).

IND enabling: Science and First-in-human use.

First in human patient safety/efficacy for AML/solid tumor.